• Edurne Sarrate, Maria-José Jiménez, Mireia Morgades, Pilar Marcos, Pilar Ricart, Susana Vives, Blanca Xicoy, Anna Torrent, María-Teresa Misis, Maria-Luisa Bordeje, Montserrat Batlle, Miriam Moreno, Juan-Manuel Sancho, Josep-Maria Ribera, and Christelle Ferra.
• Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
• Med Clin (Barc). 2020 Nov 13; 155 (9): 382-387.

IntroductionThe impact of an admission to ICU before stem cell transplantation (SCT) on post-SCT outcome is not well established.Patients And MethodsWe reviewed the medical records of patients who had received a first SCT between 2000 and 2016 in our institution. The outcome of 22 patients who required ICU admission during chemotherapy prior to SCT (ICU group) was compared with 44 matched patients (1:2) who did not need it (NO-ICU group).ResultsThere were no differences in transplant complications, in time to neutrophil and platelet recovery or in the length of hospital stay during SCT between the ICU and NO-ICU groups. However, microbiologically documented infections were more common in the ICU group (16/20) than in the NO-ICU group (18/39) (p=.027). The 5-yr overall survival probability (CI 95%) was 49% (28-70%) in the ICU vs. 45% (29-61%) in the NO-ICU group (p=.353), while the 5-yr incidence of non-relapse mortality was 32% (14-52%) and 24% (12-38%) (p=.333), respectively. Six patients (27%) in the ICU group and 8 (18%) in the NO-ICU group required admission to the ICU during or after the SCT procedure (p=.293). Twelve (54%) patients in the ICU and 22 (50%) in the NO-ICU group died, the causes of death were similar in both groups.ConclusionOur results show that admission to the ICU prior to SCT does not have a negative impact on patient outcomes following SCT and should not be considered as an exclusion criterion for SCT.Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

14 keywords...

hide…